First human dose for anti-aging therapy
Life Biosciences, an American company, has launched its first clinical trial for ER-100, a treatment based on partial cell reprogramming aimed at addressing glaucoma and age-related optic nerve damage. The initial dose was administered to a participant in the study across several U.S. cities, with the goal of evaluating the safety of the therapy and its potential to improve vision or slow the deterioration of the optic nerve by activating therapeutic genes within the eye. This marks the first-ever global trial applying cell reprogramming technology to humans, with hopes of advancing treatment for age-related diseases such as Alzheimer's and heart conditions.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)